report revenueof street estim non-
gaap ep street estim manag guid core
growth note busi track ahead origin expect
combin lower debt issuanc cost previous note increas first year
accret increas price target reflect
ep estim
result report organ revenu growth street
life scienc revenu grew organ street
estim diagnost grew organ consensu
environment grew cc street
estim oper margin improv bp yoy non-gaap ep
street estim
busi updat cepheid standout growth driven core
busi rage flu season surpass full year leica biosystem
radiomet also continu strong year end doubl digit growth
pall continu strong hsd year almost growth on-going interest
synthet biolog drive growth doubl digit product id
lsd esko/x-rit outperform videojet mix trojan
hach lsd tough comp chemtreat msd manag non-committ
potenti effect chines busi coronaviru note opportun
cepheid/idt test potenti risk across portfolio compani
manag expect non-gaap ep street ge
expect add due previous note low debt cost vs
assumpt guid non-gaap ep street
guidanc includ impact acquisit
expect close end
stock continu execut well across portfolio
alreadi rais accret estim ge bioscienc cytiva
appreci consist out-performance think core growth assumpt
ripe upsid valuat keep us neutral increas price target
reflect ep estim previous multipl
base multipl continu reflect peer premium
competit regul reimburs acquisit integr
conglomer focus healthcar environment product
ep
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
million except share per share data
updat
good sold
good sold
good sold
net incom common
compani report piper sandler co current disclosur inform compani locat
